abstract |
Novel compounds inhibiting the integrin α2βl/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2βl/GPIa-IIa-mediated activity. |